For years before GLP-1s were available, weve worked with patients on sustainable weight loss without relying on extreme calorie restriction, punishing workout plans, or diets that leave them exhausted and hungry
*Gluten-free according to EU Regulation
[12] Healthcare providers will monitor any unusual responses and can adjust treatment if any potential interaction is suspected
After scrapping a Biden-era plan to cover obesity drugs in early 2025, the Trump administration reversed course: it struck deals with Novo Nordisk and Eli Lilly in November 2025 to cut GLP-1 prices, and a voluntary Medicare demonstration begins July 1, 2026 that lets participating drug plans cover GLP-1s for weight loss with a $50 monthly copay
For the duration of the program, eligible patients will pay $35 per 30-day supply
Recent research has identified the TLR4/MyD88/NF-B pathway as playing a central role in various neurological disease models, suggesting its relevance in schizophrenia pathogenesis